...
首页> 外文期刊>Indian Journal of Endocrinology and Metabolism >Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma
【24h】

Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma

机译:在甲状腺乳头状癌的常规和滤泡变体中,B型raf激酶V600E突变与高危肿瘤特征和不良后果缺乏关联

获取原文

摘要

Introduction: Somatic B-type Raf kinase (BRAF) V600E mutation in exon 15 was frequently found in high frequencies associated with papillary thyroid cancer (PTC). The phenotype of these cancers expressed aggressive clinical and pathological features. The present study aimed to assess the prevalence of BRAF V600E mutation among conventional and follicular variants of PTC and its association with aggressive tumor factors and outcome. Study Design: Patients who were operated and received further treatment for PTC during 2012 were included in the study. BRAF V600E mutation analysis was done by extracting genomic DNA from tumor tissue. Results: Of the 59 patients included in the study, 51% harbored BRAF V600E mutation, but the mutation status was not associated with aggressive tumor factors and adverse outcome. Conclusion: BRAF V600E mutation was not significant predictor of aggressive tumor behavior in conventional and follicular variants of PTC.
机译:简介:外显子15中的体细胞B型Raf激酶(BRAF)V600E突变经常在与甲状腺乳头状癌(PTC)相关的高频发现。这些癌症的表型表现出侵略性的临床和病理特征。本研究旨在评估BRAF V600E突变在PTC常规和滤泡变体中的普遍性及其与侵袭性肿瘤因素和预后的关系。研究设计:2012年接受手术治疗并接受进一步PTC治疗的患者包括在研究中。通过从肿瘤组织中提取基因组DNA进行BRAF V600E突变分析。结果:纳入研究的59例患者中,有51%携带了BRAF V600E突变,但突变状态与侵袭性肿瘤因素和不良预后无关。结论:BRAF V600E突变不是常规和滤泡性PTC变种侵袭性肿瘤行为的重要预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号